Tag: Onglyza
-
Pancreatic Cancer Associated With Use Of Diabetes Medicines In DPP-4 Inhibitor Drug Class
Increased Risk For Patients With Newly Diagnosed Type 2 Diabetes According To Recent Medical Research Study (Posted by Tom Lamb at DrugInjuryWatch.com) Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) diabetes medicines is associated…
-
Januvia, Onglyza, Other Diabetes Drugs In DPP-4 Inhibitor Class Significantly Increase Risk Of Crohn’s Disease (CD)
But Same Medical Study Finds That DPP-4 Inhibitors Do Not Increase Risk Of Inflammatory Bowel Disease (IBD) (Posted by Tom Lamb at DrugInjuryWatch.com) Back in March 2018 we wrote this report, “Januvia,…
-
Diabetes Drugs In DPP-4 Inhibitor Class Associated With Almost Two-Times Increased Risk Of Cholangiocarcinoma
Medical Researchers Finding This Rare But Highly Fatal Cancer Call For More Investigation Into New Possible Drug Side Effect (Posted by Tom Lamb at DrugInjuryWatch.com) A recent medical study shows that the…
-
Januvia, Onglyza, And Certain Other Diabetes Drugs Linked To Inflammatory Bowel Disease (IBD)
New Study Finds Overall 75% Increase In Risk Of IBD, And Association Peaked Between 3 And 4 Years Of Use (Posted by Tom Lamb at DrugInjuryWatch.com) According to an observational study published…
-
Kombiglyze And Onglyza MDL For Federal Court Lawsuits Filed Against Responsible Drug Companies
This Diabetes Drugs Litigation Involves Heart Failure, Myocardial Infarction, And Other Cardiovascular Problems (Posted by Tom Lamb at DrugInjuryWatch.com) In February 2018 the United States Judicial Panel on Multidistrict Litigation (JPML) established…
-
Potential Safety Signal: Rhabdomyolysis May Be Linked To Onglyza, Nesina, Januvia, And Other Diabetes Drugs
FDA Was Already Investigating The Dipeptidyl Peptidase IV (DPP-IV) Inhibitor Class Of Diabetes Drugs For Kidney Or Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) According to a new FDA quarterly report,…
-
Onglyza, Nesina, And Similar Diabetes Drugs Get FDA Drug Safety Warnings About Risk Of Heart Failure Side Effect
Set Of Newer Diabetes Medications Containing Saxagliptin And Alogliptin Also Being Investigated By FDA For Increased Risk Of Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) On April 5, 2016 the FDA…
-
Onglyza, Nesina, And Similar Diabetes Drugs Get FDA Drug Safety Warnings About Risk Of Heart Failure Side Effect
Set Of Newer Diabetes Medications Containing Saxagliptin And Alogliptin Also Being Investigated By FDA For Increased Risk Of Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) On April 5, 2016 the FDA…
-
New FDA Warning That Januvia, Onglyza, Tradjenta, And Nesina Are Associated With “joint pain that can be severe and disabling”
Label Changes About Side Effects For These Type 2 Diabetes Medicines In The Drug Class Called Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Posted by Tom Lamb at DrugInjuryWatch.com) In August 2015 the FDA announced…
-
Onglyza Update: FDA May Require A New Warning About Possible Increased Risk Of Heart Failure For Diabetes Drugs Onglyza And Kombiglyze XR
April 2015 FDA Advisory Committee Voted For An Onglyza Drug Label Change About Side Effects Risks, With One Panelist Voting Of An Onglyza Recall (Posted by Tom Lamb at DrugInjuryWatch.com) As previewed…